With a population of 1.2 billion, China holds tremendous market potential for pharmaceuticals. With up-to-date and in-depth analysis, this monthly journal from Frost & Sullivan can help companies doing business in China to better understand the industry and to build a successful business in China. It supplies continuous coverage of changes in the Chinese medical industry, including regulatory issues and the monitoring and restructuring of state-owned pharmaceuticals companies.
